Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
The ASX-listed company said DurAVR THV is the first biomimetic valve of its kind, designed to mimic the performance of a healthy human heart valve.
The patent, number 11,622,853, which expires on 30 September 2042, certifies that the company has created a distinct heart valve technology with its innovative single-piece, shaped-tissue design.
Anteris also believes the strong clinical results to date are due to the distinctive features of the DurAVR design, such as the single-piece valve construction.
“The patent signifies the extraordinary work by our team of engineers around the world responsible for the design of DurAVR THV,” said CEO Wayne Paterson.
He added, “The granting of this patent enhances the broad IP protection of DurAVR, strengthening our competitive position in the TAVR field.”
Founded in 1999, Anteris Technologies is a structural heart company that develops next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.
With advancements created to last the rest of a patient’s lifetime, Anteris claims DurAVR 3D single-piece aortic heart valve replacement meets the needs of today’s younger and more active aortic stenosis patients.
The company added that the DurAVR 3D single-piece aortic heart valve’s distinctive design and the well-established advantages of its patented ADAPT tissue technology could offer aortic stenosis patients all over the world a treatment that could change their lives.
